Blockchain Registration Transaction Record

NeuroThera Expands U.S. Patents for Psychedelic-PEA Combinations

NeuroThera Labs expands U.S. patent portfolio with Clearmind for psychedelic-PEA combinations targeting depression, PTSD, and substance use disorders.

This news matters because it signals a potential breakthrough in treating some of the most pressing mental health crises, including depression, PTSD, and substance use disorders, which affect millions worldwide and often resist conventional treatments. By combining PEA with psychedelic compounds like LSD, ketamine, and ibogaine, NeuroThera and Clearmind are exploring a novel therapeutic approach that could lead to safer, more effective options. The expansion of their patent portfolio not only strengthens their intellectual property position but also accelerates the path toward clinical trials, offering hope for patients who have not responded to existing therapies. As the demand for innovative mental health solutions grows, this collaboration could pave the way for a new class of treatments, potentially transforming care for neuropsychiatric and addiction disorders.